TechBio UK w/ Nicola Richmond

Join Nicola Richmond, VP Artificial Intelligence, for a talk on using AI in the drug discovery process.

9.30 AM, Thursday 13th October 

In this workshop at the UK BioIndustry Association (BIA) TechBio conference, Nicola will discuss how AI-based tools, underpinned by comprehensive biomedical data foundations, can be used to improve the target identification and triage process in drug discovery.

She will then join in a panel discussion chaired by Justin Bryans (Charles River  Laboratories) with the other workshop speakers:

  • Jelena Aleksic (PharmEnable)
  • Vanela Bushi (Hoxton Ventures)
  • Sarah Lynagh (Fios Genomics)

Learn more about this event →

Nicola Richmond

VP Artificial Intelligence

Nicola is Vice President of AI, and is responsible for BenevolentAI’s AI strategy and ensuring the company maintains its leading position in the AI-enabled drug discovery industry. Nicola has a PhD in pure mathematics and has worked at the intersection of AI and drug discovery for 22 years.

More Posts

You Might Also Like

Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022